Comparative study between intrathecal dexmedetomidine versus intrathecal magnesium sulfate in prevention of post spinal shivering in uroscopic surger
Not Applicable
Completed
- Conditions
- SurgeryUrological and Genital Diseasespost spinal shivering
- Registration Number
- PACTR201801003001727
- Lead Sponsor
- Kasr Eini hospital, faculty of medicine, Cairo university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 105
Inclusion Criteria
1) Uroscopic surgeries.
2) ASA I and II.
3) Age 20-60years old.
Exclusion Criteria
1) Patient refusal.
2) Contraindication to spinal anesthesia e.g; coagulopathy.
3) ASA III- IV.
4) Neurological diseases e.g.; Parkinson¿s disease, Dysautonomia.
5) Endocrine diseases except diabetes mellitus.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the antishivering effects of intrathecal dexmedetomidine and magnesium sulfate in uroscopic surgery?
How does intrathecal magnesium sulfate compare to standard-of-care antishivering agents in urological procedures?
Are there specific biomarkers that predict response to intrathecal adjuvants for post-spinal shivering prevention?
What are the potential adverse events associated with intrathecal administration of dexmedetomidine versus magnesium sulfate?
What combination therapies are being explored with intrathecal adjuvants to enhance post-spinal shivering prevention in urological surgeries?